Member Info for Saint68

The counter to that JHFH is that if everyone binned the troublemakers they would be talking to themselves. By replying you’re only giving them air and sometimes it makes the board unreadable.

Absolutely gje306

So you think that we may get to £2 but refuse to buy at around 54p?? Have you appplied for this years businessman of the year award ? Bitter clown who won’t take responsibility for his own actions. If you don’t think the price will increase why would you still hold ?

Fair enough and decent counter. For me a licensing deal of some sort needs to happen asap. Hopefully Vlad has come to his senses and sees this (along with the website) as a top priority.

Points 1,2 and 3 completely agree.

Point 4 - not sure on this one as we may end up with multiple small raises and the SP would likely not increase due to the uncertainty of when the next 1 would be.

Point 5 - for me PrimaryBid isn’t great as most PI’s wouldn’t be interested in buying at a premium. Why not buy cheaper on the open market ? Also I’m not sure what PrimaryBid charge the company to use their service.

Seriously ! - where did I say it was a bad investment ? Got a decent holding and not sold 1 share. I’m just not expecting big gains for some time. Maybe take a look at yourself and all your previous predictions.

Don’t want to fall out as you post some decent stuff. I have my opinion and you have yours. Best of luck going forward.

Totally agree with all of your comments Haywain but sometimes pie in the sky figures need to be reigned in and a more realistic approach taken. I have full faith that Hemo will come good from a patient and shareholder perspective but these things take time (and a lot of money).

So you reckon 3m is enough to complete a whole trial (all phases) ?

If you think you’re getting the below at a discount then think again and, as I was once told - don’t be so thick.

An additional and under-reported opportunity to reduce the price of CAR T-cells lies in reducing the total cost of the delivery of cellular therapies to patients. Because of the complexity of delivering cellular therapies, medical centers enter elaborate, multistep negotiations with payers to pay for the entire package of care, typically in a bundle. Treating a patient with a CAR T-cell therapy generally requires (1) procedural and laboratory pretesting (eg, echocardiography and pulmonary function testing), (2) suitability review by physicians and social workers, (3) placement of an apheresis catheter (typically under a local anesthetic), (4) leukapheresis, (5) CAR T-cell production and return shipment to the medical center, (6) treatment with lymphodepleting chemotherapy, (7) treatment with CAR T-cell therapy, (8) response assessments (eg, in lymphoma with fluorodeoxyglucose-positron emission tomography scans, or in ALL with bone marrow biopsy plus flow cytometry), and (9) recovery from toxicities.

jhfh - it definitely is not enough to run a complete trial with 20 patients.

i’ll be surprised if it’s enough for phase 1 let alone the remaining phases. totally agree that they’ll need 10’s of millions and 3m is like ******* into the wind.

Hiki - on your comment “ Mr India made the outrageous claim about an hour ago that Hemo were fully funded for trials and nobody says a thing” - it’s probably because most on here have him in the bin so have no idea what he’s saying. He’s a menace who changes his stance depending whether he wants to buy or sell.

Sorry JHFH but I have to disagree and that 3m is not enough to run a trial for 20 patients. It may be enough to get us part way through phase 1 but no more. IMO we need a collaboration asap to avoid another round of funding.

If you want to know what’s going on do some f’in research. All of 2 months - well done on the long term hold.

Bruno - of course the BOD and DS have shareholder value at heart as they’re the biggest shareholders you plum. If you really think they couldn’t give a monkeys then you need help.

Essar have a base in Hong Kong

Only a moron would put a stop loss on an AIM share.

I don't think do Chris - they're Queelds unless someone comes forward to claim them.

Sorry - my error - 130,000 shares = £65,000

"Concurrently with the Placing, certain Directors of the Company have subscribed for, in aggregate, 130,000 Direct Subscription Shares pursuant to the Direct Subscription at the Offer Price."

Mac - have you read this mornings RNS ?

Bed wetting